HPS Pharmacies wish to give notice that Pfizer is continuing to experience a supply interruption for Clopine® Suspension as follows:
Clopine® SuspensionClozapine 50 mg/mL ARTG 142239
This is a long-term supply issue. Normal supplies of Clopine® Suspension are expected to return in January 2025. This supply interruption does not affect Clopine® tablets.
Versacloz® Suspension is an internationally registered brand of clozapine oral suspension that has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
Important points to note regarding Versacloz® Suspension:
- Versacloz® Suspension appears less viscous than Clopine® Suspension and may have a slightly different taste;
- Unlike Clopine® Suspension, Versacloz® Suspension does not need to be shaken 24 hours before the first use. It should still be shaken for 10 seconds prior to withdrawing each dose;
- Patients should continue to be monitored on ClopineCentral™, noting the tradename of medicine being used; and
- Versacloz® Suspension is subsidised on the Pharmaceutical Benefits Scheme (PBS).
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates